← All trials
NCT06702124
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2023
- Primary completion
- Jul 31, 2025
- Completion date
- Apr 30, 2026
- First posted
- Nov 22, 2024
- Last posted
- Nov 22, 2024
- Enrollment
- 348
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- I.R.C.C.S. Fondazione Santa LuciaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.